Oculis (OCS) to Announce Earnings on Thursday

Oculis (NASDAQ:OCS) is expected to release its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect the company to post earnings of ($0.48) per share and revenue of $0.2340 million for the quarter. Interested persons may visit the the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Thursday, August 6, 2026 at 4:00 PM ET.

Oculis (NASDAQ:OCS) last released its quarterly earnings results on Friday, May 8th. The company reported ($0.63) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.14). Oculis had a negative return on equity of 56.78% and a negative net margin of 8,460.67%.The company had revenue of $0.26 million for the quarter, compared to analyst estimates of $0.25 million. On average, analysts expect Oculis to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Oculis Trading Up 5.1%

NASDAQ OCS opened at $11.89 on Tuesday. Oculis has a 12 month low of $10.52 and a 12 month high of $34.47. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.18 and a quick ratio of 5.18. The company has a market capitalization of $689.43 million, a price-to-earnings ratio of -5.58 and a beta of 0.44. The company’s fifty day moving average price is $13.43 and its two-hundred day moving average price is $22.63.

Institutional Trading of Oculis

Large investors have recently added to or reduced their stakes in the company. Perceptive Advisors LLC acquired a new position in Oculis during the fourth quarter worth $9,862,000. SR One Capital Management LP lifted its position in shares of Oculis by 98.8% in the fourth quarter. SR One Capital Management LP now owns 641,022 shares of the company’s stock worth $12,801,000 after buying an additional 318,522 shares during the last quarter. Alyeska Investment Group L.P. boosted its stake in shares of Oculis by 152.3% during the 4th quarter. Alyeska Investment Group L.P. now owns 331,332 shares of the company’s stock worth $6,617,000 after acquiring an additional 200,000 shares in the last quarter. Alps Advisors Inc. bought a new stake in shares of Oculis during the 4th quarter worth about $938,000. Finally, Marshall Wace LLP acquired a new position in shares of Oculis during the 4th quarter valued at about $914,000. 22.30% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on OCS shares. Guggenheim lowered their price objective on shares of Oculis from $75.00 to $45.00 and set a “buy” rating for the company in a research report on Monday, June 1st. Stifel Nicolaus reduced their price objective on shares of Oculis from $50.00 to $40.00 and set a “buy” rating for the company in a report on Monday, June 1st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Oculis in a report on Friday, July 17th. Needham & Company LLC lowered their price target on Oculis from $46.00 to $38.00 and set a “buy” rating on the stock in a research report on Monday, June 1st. Finally, Wall Street Zen cut Oculis from a “sell” rating to a “strong sell” rating in a research note on Sunday, July 12th. Nine investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $38.33.

About Oculis

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.